Prenetics Global Limited (NASDAQ:PRE – Free Report) – Sidoti reduced their Q3 2026 earnings per share estimates for Prenetics Global in a note issued to investors on Wednesday, July 15th. Sidoti analyst A. Hantman now expects that the company will earn ($0.85) per share for the quarter, down from their previous estimate of ($0.48). The consensus estimate for Prenetics Global’s current full-year earnings is ($1.40) per share. Sidoti also issued estimates for Prenetics Global’s Q4 2026 earnings at ($0.95) EPS, Q1 2027 earnings at ($0.51) EPS, Q2 2027 earnings at ($0.25) EPS, Q3 2027 earnings at ($0.01) EPS, Q4 2027 earnings at $0.16 EPS and FY2027 earnings at ($0.60) EPS.
A number of other research analysts have also recently issued reports on the company. Benchmark lifted their target price on Prenetics Global from $30.00 to $40.00 and gave the company a “buy” rating in a research report on Wednesday. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Prenetics Global in a report on Tuesday, April 21st. Four equities research analysts have rated the stock with a Buy rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, Prenetics Global has a consensus rating of “Moderate Buy” and an average price target of $34.25.
Prenetics Global Trading Down 3.4%
NASDAQ PRE opened at $18.91 on Friday. The firm has a market capitalization of $319.01 million, a price-to-earnings ratio of -4.13 and a beta of 0.26. The firm’s 50 day simple moving average is $18.66 and its 200 day simple moving average is $18.47. Prenetics Global has a 1 year low of $7.18 and a 1 year high of $23.63.
Prenetics Global (NASDAQ:PRE – Get Free Report) last released its quarterly earnings results on Wednesday, June 10th. The company reported ($0.56) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.49) by ($0.07). The business had revenue of $35.95 million during the quarter, compared to analyst estimates of $36.00 million. Prenetics Global had a negative net margin of 62.45% and a negative return on equity of 20.33%.
Institutional Trading of Prenetics Global
A number of large investors have recently bought and sold shares of the business. Jane Street Group LLC acquired a new stake in Prenetics Global during the fourth quarter worth approximately $1,302,000. 683 Capital Management LLC bought a new position in shares of Prenetics Global during the 4th quarter worth approximately $1,181,000. Millennium Management LLC acquired a new stake in shares of Prenetics Global during the 4th quarter worth approximately $810,000. Marshall Wace LLP acquired a new stake in shares of Prenetics Global during the 4th quarter worth approximately $788,000. Finally, UBS Group AG increased its stake in shares of Prenetics Global by 581.9% in the 3rd quarter. UBS Group AG now owns 46,561 shares of the company’s stock valued at $619,000 after acquiring an additional 39,733 shares in the last quarter. 25.01% of the stock is currently owned by institutional investors and hedge funds.
Trending Headlines about Prenetics Global
Here are the key news stories impacting Prenetics Global this week:
- Positive Sentiment: Benchmark raised its price target on Prenetics Global (NASDAQ: PRE) to $40 from $30 and kept a Buy rating, implying significant upside potential.
- Positive Sentiment: Despite recent volatility, analysts still view the stock favorably overall, with the latest consensus recommendation reported as “Moderate Buy.” Prenetics Global Limited (NASDAQ:PRE) Given Consensus Recommendation of “Moderate Buy” by Analysts
- Neutral Sentiment: Sidoti also published long-term earnings estimates for 2028, including projected profitability, which may support the bull case but does not change near-term fundamentals.
- Negative Sentiment: Sidoti sharply cut several near- and medium-term EPS estimates for Prenetics Global, including Q3 2026, Q4 2026, Q1 2027, Q2 2027, Q3 2027, Q4 2027, and FY2027, reinforcing expectations for continued losses in the near term.
Prenetics Global Company Profile
Prenetics Global (NASDAQ: PRE) is a molecular diagnostics and genetic testing company that delivers a broad range of laboratory and at-home testing solutions. The company’s core offerings include next-generation sequencing (NGS) panels for hereditary health risks, pharmacogenomic reports to guide medication choices, and comprehensive consumer DNA testing services. In addition to genetic insights, Prenetics provides infectious disease diagnostics—most notably real-time PCR testing for pathogens such as SARS-CoV-2—through an integrated platform that combines sample collection, laboratory processing and digital reporting.
Serving both business-to-consumer and business-to-business markets, Prenetics operates a network of laboratories and service centers across Asia Pacific, Europe, the Middle East and North America.
Featured Articles
- Five stocks we like better than Prenetics Global
- Has Broadcom Become Too Expensive for Its AI Story?
- Why Abbott Laboratories Stock Is Suddenly Winning Back Wall Street
- Revving Up Returns: Big Banks Race Through the Rate Plateau
- Why Uber’s Biggest Deal Yet Could Unlock Its Next Growth Phase
Receive News & Ratings for Prenetics Global Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Prenetics Global and related companies with MarketBeat.com's FREE daily email newsletter.
